Goldman Sachs Downgrades Ultragenyx to Neutral After Setrusumab Trial Miss

Goldman Sachs downgraded Ultragenyx from Buy to Neutral and slashed its price target to $25 after setrusumab Phase 3 miss in osteogenesis imperfecta. GTX-102 in Angelman syndrome now key focus, but risks remain.